ArticleHemaSphere2025

Serum TARC dynamics during anti-PD1-based first-line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial.

Wouter J Plattel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.